Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new name marks a critical branding milestone for the company. Genprex’s REQORSA (pronounced “re-KORE-suh”) immunogene therapy features the company’s exclusive ONCOPREX(TM) nanoparticle delivery system that delivers cancer-fighting genes. The name will be resubmitted to the FDA for final review and approval after all required clinical trials are completed; that final approval is based on the FDA’s approval of the product candidate. The new name was based on FDA’s guidelines for the submission and evaluation of proprietary names. Genprex selected the name based on a comprehensive review of name candidates, including a study of healthcare practitioners across the country to guarantee accurate prescription and safety interpretation of the name. “We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer,” said Genprex president and CEO Rodney Varner in the press release. “This name approval also marks an important milestone in our overall branding strategy, giving us a unique, easily understood name people can associate with the Genprex brand and mission.”
To view the full press release, visit https://nnw.fm/EIXf0
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork